Pharmacologic IRE1 Activation Rewires Cholesterol Metabolism to Suppress TH17 Differentiation
Authors:
- Keishla Sánchez OrtizKOKeishla Sánchez Ortiz
- Priyadarshini ChatterjeePCPriyadarshini Chatterjee
- William DionWDWilliam Dion
- Meera PannikkatMPMeera Pannikkat
- Sergei KutseikinSKSergei Kutseikin
- Taylor BassoTBTaylor Basso
- Prakhyat MathurPMPrakhyat Mathur
- Stanislav DikiySDStanislav Dikiy
- Jessica E ThaxtonJTJessica E Thaxton
- Luke WisemanLWLuke Wiseman
- Alejandra MendozaAMAlejandra Mendoza
Preprint
Abstract
T helper 17 (TH17) cells are a subset of CD4⁺ T cells that coordinate immune responses against extracellular bacterial and fungal pathogens. Dysregulation of TH17 cell responses drives excessive inflammation and contributes to the development of chronic inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease, and multiple sclerosis. Here, we demonstrate that pharmacologic activation of the IRE1 signaling arm of the unfolded protein response (UPR) selectively reduces differentiation of TH17 cells without impacting the differentiation of other helper T cell subsets. We show that IRE1 activation suppresses TH17 differentiation by limiting intracellular cholesterol in differentiating TH17 cells through the increased degradation of the rate-limiting cholesterol biosynthesis enzyme HMGCR. Our findings identify IRE1 as a metabolic checkpoint regulating cholesterol biosynthesis in differentiating TH17 cells and demonstrate that its pharmacological activation suppresses TH17 differentiation, highlighting a potential therapeutic strategy for limiting TH17-driven inflammatory diseases.Funding Information
- National Institutes of Health (AG046495)
- National Institutes of Health (DK137470)
- National Institutes of Health (T32 TR004396)
- National Institutes of Health (F32 DK148145)
- Prebys Foundation